The role of vitamin D in reducing gastrointestinal disease risk and assessment of individual dietary intake needs: Focus on genetic and genomic technologies

Molecular Nutrition and Food Research

Volumn 60, Issue 1, 2016, Pages 119-133

  Ferguson, Lynnette R ^a,b   Laing, Bobbi ^b   Marlow, Gareth ^b   Bishop, Karen ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

BLOOD; COMPLICATION; COST BENEFIT ANALYSIS; DIET; DIETARY SUPPLEMENT; DRUG EFFECTS; FORTIFIED FOOD; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; GENOMICS; HUMAN; INTESTINE FLORA; METABOLISM; MICROBIOLOGY; NUTRITIONAL ASSESSMENT; NUTRITIONAL REQUIREMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; VITAMIN D DEFICIENCY;

COST-BENEFIT ANALYSIS; DIET; DIETARY SUPPLEMENTS; FOOD, FORTIFIED; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; GENOMICS; HUMANS; NUTRITION ASSESSMENT; NUTRITIONAL REQUIREMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84952985412     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201500243     Document Type: Review

References (130)

1. Day, A., Lemberg, D., Gearry, R., Inflammatory bowel disease in Australasian children and adolescents. Gastroenterol. Res. Pract. 2014, 703890, doi: 10.1155/2014/703890.
2. Lemberg, D. A., Day, A. S., Crohn disease and ulcerative colitis in children: an update for 2014. J. Paediatr. Child Health 2015, 51, 266-270.
3. Blakely, T., Atkinson, J., Kvizhinadze, G., Wilson, N. et al., Patterns of cancer care costs in a country with detailed individual data. Med. Care 2015, 53, 302-309.
4. Spedding, S., Vanlint, S., Morris, H., Scragg, R., Does vitamin D sufficiency equate to a single serum 25-hydroxyvitamin D level or are different levels required for non-skeletal diseases? Nutrients 2013, 5, 5127-5139.
5. Grant, W. B., The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. Lancet Diabetes Endocrinol. 2014, 2, 364.
6. Grant, W. B., 25-hydroxyvitamin D and breast cancer, colorectal cancer, and colorectal adenomas: case-control versus nested case-control studies. Anticancer Res. 2015, 35, 1153-1160.
7. Holick, M. F., Vitamin D deficiency. N. Engl. J. Med. 2007, 357, 266-281.
8. Schottker, B., Haug, U., Schomburg, L., Kohrle, J. et al., Strong associations of 25-hydroxyvitamin D concentrations with all-cause, cardiovascular, cancer, and respiratory disease mortality in a large cohort study. Am. J. Clin. Nutr. 2013, 97, 782-793.
9. Carlberg, C., Genome-wide (over) view on the actions of vitamin D. Front Physiol. 2014, 5, 167.
10. Jablonski, N. G., Human skin pigmentation as an example of adaptive evolution. Proc. Am. Philos. Soc. 2012, 156, 45-57.
11. Jablonski, N., The evolution of human skin colouration and its relevance to health in the modern world. J. R. Coll. Physicians Edinb. 2012, 42, 58-63.
12. Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V. et al., An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 2006, 444, 1027-1131.
13. Gentschew, L., Ferguson, L. R., Role of nutrition and microbiota in susceptibility to inflammatory bowel diseases. Mol. Nutr. Food Res. 2012, 56, 524-535.
14. Ferguson, L. R., Nutrigenetics, nutrigenomics and inflammatory bowel diseases. Exp. Rev. Clin. Immunol. 2013, 9, 717-726.
15. Goldsmith, J. R., Sartor, R. B., The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J. Gastroenterol. 2014, 49, 785-798.
16. Ames, B. N., McCann, J. C., Stampfer, M. J., Willett, W. C., Evidence-based decision making on micronutrients and chronic disease: long-term randomized controlled trials are not enough. Am. J. Clin. Nutr. 2007, 86, 522-3, author reply 523-524.
17. Bischoff-Ferrari, H. A., Orav, E. J., Willett, W. C., Dawson-Hughes, B., The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes. The Lancet Diabetes Endocrinol. 2014, 2, 363-364.
18. Heaney, R. P., Guidelines for optimizing design and analysis of clinical studies of nutrient effects. Nutr. Rev. 2014, 72, 48-54.
19. Baghurst, K., Record, S. Re-analysis of the 1995 National Nutrition Survey. Adelaide: CSIRO 2002.
20. Ovesen, L., Brot, C., Jakobsen, J., Food contents and biological activity of 25-hydroxyvitamin D: a vitamin d metabolite to be reckoned with? Ann. Nutr. Metab. 2003, 47, 107-113.
21. Crowe, F. L., Steur, M., Allen, N. E., Appleby, P. N. et al., Plasma concentrations of 25-hydroxyvitamin D in meat eaters, fish eaters, vegetarians and vegans: results from the EPIC-Oxford study. Public Health Nutr. 2011, 14, 340-346.
22. Ross, A. C., Taylor, C. L., Yaktine, A. L., Del Valle, H. B., Eds. Dietary Reference Intakes for Calcium and Vitamin D. Institute of Medicine of the National Academies, Washington DC, 2011.
23. National Institutes of Health. Vitamin D Fact Sheet for Health Professionals. Available at: https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/
24. Lips, P., Worldwide status of vitamin D nutrition. J. Steroid Biochem. Mol. Biol. 2010, 121, 297-300.
25. Douglas, B., Vitamin D and health in adults in Australia and New Zealand. Med. J. Aust. 2013, 199, 394-394.
26. Green, T. J., Skeaff, C. M., Rockell, J. E., Milk fortified with the current adequate intake for vitamin D (5 μg) increases serum 25-hydroxyvitamin D compared to control milk but is not sufficient to prevent a seasonal decline in young women. Asia Pac. J. Clin. Nutr. 2010, 19, 195-199.
27. Houghton, L. A., Gray, A. R., Szymlek-Gay, E. A., Heath, A. L. et al., Vitamin D-fortified milk achieves the targeted serum 25-hydroxyvitamin D concentration without affecting that of parathyroid hormone in New Zealand toddlers. J. Nutr. 2011, 141, 1840-1846.
28. Guo, C. F, Gombart, A., The antibiotic effects of vitamin D. Endocr. Metab. Immune Disord. Drug Targets 2014, 14, 255-266.
29. Guo, C., Sinnott, B., Niu, B., Lowry, M. B. et al., Synergistic induction of human cathelicidin antimicrobial peptide gene expression by vitamin D and stilbenoids. Mol. Nutr. Food Res. 2014, 58, 528-536.
30. Ridlon, J. M., Kang, D. J., Hylemon, P. B., Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 2006, 47, 241-259.
31. Cheng, J., Fang, Z. Z., Kim, J. H., Krausz, K. W. et al., Intestinal CYP3A4 protects against lithocholic acid-induced hepatotoxicity in intestine-specific VDR-deficient mice. J. Lipid Res. 2014, 55, 455-465.
32. Ajouz, H., Mukherji, D., Shamseddine, A., Secondary bile acids: an underrecognized cause of colon cancer. World J. Surg. Oncol. 2014, 12, 1-5.
33. Makishima, M., Lu, T. T., Xie, W., Whitfield, G. K. et al., Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296, 1313-1316.
34. Jones, M. L., Martoni, C. J., Prakash, S., Oral supplementation with probiotic L. Reuteri NCIMB 30242 increases mean circulating 25-hydroxyvitamin D: a post hoc analysis of a randomized controlled trial. Source J. Clin. Endocrinol. Metab. 2013, 98, 2944-2951.
35. Wu, S., Liao, A. P., Xia, Y., Li, Y. C. et al., Vitamin D receptor negatively regulates bacterial-stimulated NF-κB activity in intestine. Am. J. Pathol. 2010, 177, 686-697.
36. Wu, S., Zhang, Y. G., Lu, R., Xia, Y. et al. Intestinal epithelial vitamin D receptor deletion leads to defective autophagy in colitis. Gut 2015, 64, 1082-1094.
37. Lehrer, R. I., Ganz, T., Cathelicidins: a family of endogenous antimicrobial peptides. Curr. Opin. Hematol. 2002, 9, 18-22.
38. Godchaux, W., Leadbetter, E., Sulfonolipids of gliding bacteria structure of the N-acylaminosulfonates. J. Biol. Chem. 1984, 259, 2982-2990.
39. Marshall, T. G., Bacterial capnine blocks transcription of human antimicrobial peptides. in: Metagenomics 2007, University of California, San Diego, CA, USA 2007.
40. Salazar, J. C., Duhnam-Ems, S., La Vake, C., Cruz, A. R. et al., Activation of human monocytes by live Borrelia burgdorferi generates TLR2-dependent and-independent responses which include induction of IFN-Β. PLoS Pathog. 2009, 5, e1000444.
41. Xu, Y., Xie, J., Li, Y., Yue, J. et al., Using a cDNA microarray to study cellular gene expression altered by mycobacterium tuberculosis. Chin. Med. J. (Engl.) 2003, 116, 1070-1073.
42. Roy, S., Frodsham, A., Saha, B., Hazra, S. et al., Association of vitamin D receptor genotype with leprosy type. J. Infect. Dis. 1999, 179, 187-191.
43. He, Q., Ananaba, G.A., Patrickson, J., Pitts, S. et al., Chlamydial infection in vitamin D receptor knockout mice is more intense and prolonged than in wild-type mice. J. Steroid Biochem. Mol. Biol. 2013, 135, 7-14.
44. Liu, P. T., Wheelwright, M., Teles, R., Komisopoulou, E. et al., MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat. Med. 2012, 18, 267-273.
45. Yenamandra, S., Lundin, A., Arulampalam, V., Yurchenko, M. et al., Expression profile of nuclear receptors upon Epstein-Barr virus induced B cell transformation. Exp. Oncol. 2009, 31, 92-96.
46. Ooi, J. H., Li, Y., Rogers, C. J., Cantorna, M. T., Vitamin D regulates the gut microbiome and protects mice from dextran sodium sulfate-induced colitis. J. Nutr. 2013, 143, 1679-1686.
47. Yu, S., Bruce, D., Froicu, M., Weaver, V. et al., Failure of T cell homing, reduced CD4/CD8 alpha alpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc. Natl. Acad. Sci. USA 2008, 105, 20834-20839.
48. Mai, V., McCrary, Q. M., Sinha, R., Glei, M., Associations between dietary habits and body mass index with gut microbiota composition and fecal water genotoxicity: An observational study in African American and Caucasian American volunteers. Nutr J. 2009, 8, 49.
49. Ly, N. P., Litonjua, A., Gold, D. R., Celedón, J. C., Gut microbiota, probiotics, and vitamin D: interrelated exposures influencing allergy, asthma, and obesity? J. Allergy Clin. Immunol. 2011, 127, 1087-1094.
50. Podd, D. Hypovitaminosis D: a common deficiency with pervasive consequences. JAAPA 2015, 28, 20-26.
51. Pludowski, P., Holick, M. F., Pilz, S., Wagner, C. L. et al., Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality-a review of recent evidence. Autoimmunity Rev. 2013, 12, 976-989.
52. Fraser, W. D., Milan, A. M., Vitamin D assays: past and present debates, difficulties, and developments. Calcif. Tissue Int. 2013, 92, 118-127.
53. Hollis, B. W., Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Curr. Opin. Endocrinol. Diabetes Obes. 2008, 15, 489-494.
54. Vitamin D External Quality Assessment Scheme. DEQAS Participant Portal. Available at: http://www.deqas.org/
55. Ministry of Health New Zealand. Bowel Cancer Programme. Available at: http://www.health.govt.nz/our-work/diseases-and-conditions/cancer-programme/bowel-cancer-programme
56. Shah, A. B., Sarfati, D., Blakely, T., Atkinson, J. et al., Trends in colorectal cancer incidence rates in New Zealand, 1981-2004. ANZ J. Surg. 2012, 82, 258-264.
57. Nutrient Reference Values for Australia and New Zealand: Including Recommended Dietary Intakes., Commonwealth of Australia, 2006.
58. Harding, W. R., Russell, C. E., Davidson, F., Prior, I. A., Dietary surveys from the Tokelau Island migrant study. Ecol. Food Nutr. 1986, 19, 83-97.
59. Feldman, D., Krishnan, A. V., Swami, S., Giovannucci, E. et al., The role of vitamin D in reducing cancer risk and progression. Nat. Rev. Cancer 2014, 14, 342-357.
60. Song, M., Nishihara, R., Wang, M., Chan, A. T. et al. Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. Gut 2015. DOI:10.1136/gutjnl-2014-308852
61. Ng, K. M., Alan, P., Venook, S. K., Prolonged survival in mCRC linked to high pretreatment vitamin D. Available at: http://www.colorectal-cancer.ca/en/news-and-resources/prolonged-vitamin/
62. Song, M., Garrett, W. S., Chan, A. T., Nutrients, foods, and colorectal cancer prevention. Gastroenterology 2015, 148, 1244-1260.
63. Rheem, D. S., Baylink, D. J., Olafsson, S., Jackson, C. S. et al., Prevention of colorectal cancer with Vitamin D. Scand. J. Gastroenterol. 2010, 45, 775-784.
64. Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M. et al., Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2011, 96, 1911-1930.
65. Zhiqin, W., Palaniappan, S., Ali, R., Affendi, R., Inflammatory bowel disease-related colorectal cancer in the Asia-Pacific region: past, present, and future. Intest. Res. 2014, 12, 194-204.
66. Tomasello, G., Tralongo, P., Damiani, P., Sinagra, E. et al., Dismicrobism in inflammatory bowel disease and colorectal cancer: changes in response of colocytes. World J. Gastroenterol. 2014, 20, 18121.
67. Lai, K. K., Horvath, B., Xie, H., Wu, X. et al. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflamm. Bowel Dis. 2015, 21, 378-384.
68. Neovius, M., Arkema, E. V., Blomqvist, P., Ekbom, A. et al., Patients with ulcerative colitis miss more days of work than the general population, even following colectomy. Gastroenterology 2013, 144, 536-543.
69. Herszenyi, L., Barabas, L., Miheller, P., Tulassay, Z., Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk. Dig. Dis. 2015, 33, 52-57.
70. Dekker, E., van Gulik, T., Colorectal cancer: what the clinician wants to know. Cancer Imaging 2005, 5 Spec No A, S127-S132.
71. Ananthakrishnan, A. N., Cheng, S., Cai, T., Cagan, A. et al., Association between reduced plasma 25-hydroxyvitamin D and increased risk of cancer in patients with inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 2014, 12, 821-827.
72. Molodecky, N. A., Soon, S., Rabi, D. M., Ghali, W. A. et al., Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012, 142, 46-54. e42.
73. Gearry, R. B., Leong, R. W., Inflammatory bowel disease in Asia: the start of the epidemic? J. Gastroenterol. Hepatol. 2013, 28, 899-900.
74. Basson, A. Vitamin D and Crohn's disease in the adult patient: a review. JPEN J. Parenter. Enteral Nutr. 2014, 38, 438-458.
75. Carvalho, A. Y., Bishop, K. S., Han, D. Y., Ellett, S. et al., The role of vitamin D level and related single nucleotide polymorphisms in Crohn's disease. Nutrients 2013, 5, 3898-3909.
76. Kini, G. P., Young, B., Herbison, P., Schultz, M., Does seasonal level of serum 25-OH vitamin D correlate with the activity of Crohn's disease? NZ Med. J. 2014, 127, 51-59.
77. Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H. et al., Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012, 491, 119-124.
78. Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P. et al., Genetic determinants of Crohn's disease and ulcerative colitis phenotypes in 34, 819 patients. Lancet. Available at: http://hdl.handle.net/2268/180573
79. Cantorna, M. T., McDaniel, K., Bora, S., Chen, J. et al., Vitamin D, immune regulation, the microbiota, and inflammatory bowel disease. Exp. Biol. Med. 2014, 239, 1524-1530.
80. Maguire, L. H., Song, M., Strate, L. E., Giovannucci, E. L. et al., Higher serum levels of vitamin D are associated with a reduced risk of diverticulitis. Clin. Gastroenterol. Hepatol. 2013, 11, 1631-1635.
81. Maguire, L. H., Song, M., Strate, L. L., Giovannucci, E. L. et al., Association of geographic and seasonal variation with diverticulitis admissions. JAMA Surg. 2015, 150, 74-77.
82. Nguyen, G. C., Sam, J., Anand, N., Epidemiological trends and geographic variation in hospital admissions for diverticulitis in the United States. World J. Gastroenterol. 2011, 17, 1600-1605.
83. Camilleri, M., Williams, D. E., Economic burden of irritable bowel syndrome. PharmacoEconomics 2000, 17, 331-338.
84. Canavan, C., West, J., Card, T., The epidemiology of irritable bowel syndrome. Clin. Epidemiol. 2014, 6, 71.
85. Sprake, E. F., Grant, V. A., Corfe, B. M., Vitamin D3 as a novel treatment for irritable bowel syndrome: single case leads to critical analysis of patient-centred data. BMJ Case Rep. 2012, 2012, 10.1136/bcr-2012-007223.
86. Wang, B., Jing, Z., Li, C., Xu, S. et al., Blood 25-hydroxyvitamin D levels and overall mortality in patients with colorectal cancer: a dose-response meta-analysis. Eur. J. Cancer 2014, 50, 2173-2175.
87. Zgaga, L., Theodoratou, E., Farrington, S. M., Din, F. V. et al., Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J. Clin. Oncol. 2014, 32, 2430-2439.
88. Toriola, A. T., Nguyen, N., Scheitler-Ring, K., Colditz, G. A., Circulating 25-hydroxyvitamin D levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol. Biomarkers Prev. 2014, 23, 917-933.
89. Wesa, K. M., Segal, N. H., Cronin, A. M., Sjoberg, D. D. et al., Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer: a retrospective analysis. Nutr. Cancer 2015, 67, 424-430.
90. Li, M., Chen, P., Li, J., Chu, R. et al., Review: the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 2014, 99, 2327-2336.
91. Mohr, S. B., Gorham, E. D., Kim, J., Hofflich, H. et al., Could vitamin D sufficiency improve the survival of colorectal cancer patients? J. Steroid Biochem. Mol. Biol. 2015, 148, 239-244.
92. Winkels, R. M., Heine-Bröring, R. C., Van Zutphen, M., van Harten-Gerritsen, S. et al., The COLON study: colorectal cancer: longitudinal, observational study on nutritional and lifestyle factors that may influence colorectal tumour recurrence, survival and quality of life. BMC Cancer 2014, 14, 374.
93. So, J. Y., Suh, N., Targeting cancer stem cells in solid tumors by vitamin D. J. Steroid Biochem. Mol. Biol. 2015, 148, 79-85.
94. Ferguson, L. R., Denny, W. A., COMMENTARY: pre-emptive nutrition: refining the targets of drugs targeted to colorectal cancer. Curr. Cancer Drug Targets 2015, 15, 173-175.
95. Ghaly, S., Lawrance, I., The role of vitamin D in gastrointestinal inflammation. Expert Rev. Gastroenterol. Hepatol. 2014, 8, 909-923.
96. Meeker, S., Seamons, A., Paik, J., Treuting, P. M. et al., Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res. 2014, 74, 4398-4408.
97. Kosmowska-Miskow, A., The role of vitamin D3 in inflammatory bowel diseases. Adv. Clin. Exp. Med. 2014, 23, 497-504.
98. Durup, D., Jørgensen, H., Christensen, J., Schwarz, P. et al., Reverse J-shaped association of all-cause mortality with serum 25-hydroxyvitamin D in general practice: The CopD study. J. Clin. Endocrinol. Metab. 2012, 97, 2644-2652.
99. Ensrud, K. E., Blackwell, T. L., Cauley, J. A., Cummings, S. R. et al., Circulating 25, hydroxyvitamin D levels and frailty in older men: the osteoporotic fractures in men study. J. Am. Geriatr. Soc. 2011, 59, 101-106.
100. Ensrud, K. E., Ewing, S. K., Fredman, L., Hochberg, M. C. et al., Circulating 25-hydroxyvitamin D levels and frailty status in older women. J. Clin. Endocrinol. Metab. 2010, 95, 5266-5273.
101. Garland, C. F., Kim, J. J., Mohr, S. B., Gorham, E. D. et al., Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. Am. J. Public Health 2014, 104, e43-e50.
102. Shelling, A. N., Ferguson, L. R., Genetic variation in human disease and a new role for copy number variants. Mutat. Res. 2007, 622, 33-41.
103. Maier, C. J., Maier, R. H., Rid, R., Trost, A. et al., PIM-1 kinase interacts with the DNA binding domain of the vitamin D receptor: a further kinase implicated in 1, 25-(OH)2D3 signaling. BMC Mol. Biol. 2012, 13, 18-2199, 13-18.
104. Wang, T. J., Zhang, F., Richards, J. B., Kestenbaum, B. et al., Common genetic determinants of vitamin D insufficiency: a genome-wide association study. The Lancet 2010, 376, 180-188.
105. Hossein-nezhad, A., Spira, A., Holick, M. F., Influence of vitamin D status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial. PloS One 2013, 8, e58725.
106. Bishop, K. S., Ferguson, L. R., The interaction between epigenetics, nutrition and the development of cancer. Nutrients 2015, 7, 922-947.
107. Saccone, D., Asani, F., Bornman, L., Regulation of the vitamin D receptor gene by environment, genetics and epigenetics. Gene 2015, 561, 171-180.
108. Hossein-nezhad, A., Holick, M. F., Optimize dietary intake of vitamin D: an epigenetic perspective. Curr. Opin. Clin. Nutr. Metab. Care 2012, 15, 567-579.
109. Kussmann, M., Van Bladeren, P. J., The extended nutrigenomics - understanding the interplay between the genomes of food, gut microbes, and human host. Front. Genet. 2011, 2, 21.
110. Tarroni, P., Villa, I., Mrak, E., Zolezzi, F. et al., Microarray analysis of 1, 25 (OH) 2D3 regulated gene expression in human primary osteoblasts. J. Cell. Biochem. 2012, 113, 640-649.
111. O'Sullivan, A., Gibney, M. J., Connor, A. O., Mion, B. et al., Biochemical and metabolomic phenotyping in the identification of a vitamin D responsive metabotype for markers of the metabolic syndrome. Mol. Nutr. Food Res. 2011, 55, 679-690.
112. O'Donovan, C. B., Walsh, M. C., Nugent, A. P., McNulty, B. et al., Use of metabotyping for the delivery of personalised nutrition. Mol. Nutr. Food Res. 2015, 59, 377-385.
113. Elnenaei, M. O., Chandra, R., Mangion, T., Moniz, C., Genomic and metabolomic patterns segregate with responses to calcium and vitamin D supplementation. Br. J. Nutr. 2011, 105, 71-79.
114. Ferguson, L. R., Potential value of nutrigenomics in Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 2012, 9, 260-270.
115. Tang, H., Mirshahidi, S., Senthil, M., Kazanjian, K. et al., Down-regulation of LXR/RXR activation and negative acute phase response pathways in colon adenocarcinoma revealed by proteomics and bioinformatics analysis. Cancer Biomark. 2014, 14, 313-324.
116. Al-Daghri, N. M., Garbis, S. D., The need for serological markers of response to vitamin D status optimization: a case for quantitative serum proteomics. Bioanalysis 2014, 6, 721-723.
117. Wang, W. L., Xu, S. Y., Ren, Z. G, Tao, L. et al., Application of metagenomics in the human gut microbiome. World J. Gastroenterol. 2015, 21, 803-814.
118. Kim, Y., Koh, I., Rho, M., Deciphering the human microbiome using next-generation sequencing data and bioinformatics approaches. Methods 2015, 79-80, 52-59.
119. Maccaferri, S., Biagi, E., Brigidi, P., Metagenomics: key to human gut microbiota. Dig. Dis. 2011, 29, 525-530.
120. Fodor, A., Utilizing "omics" tools to study the complex gut ecosystem. in: Microbial Endocrinology: The Microbiota-Gut-Brain Axis in Health and Disease., Springer 2014, pp. 25-38.
121. Powe, C. E., Evans, M. K., Wenger, J., Zonderman, A. B. et al., Vitamin D-binding protein and vitamin D status of black Americans and White Americans. N. Engl. J. Med. 2013, 369, 1991-2000.
122. Grant, W. B., Peiris, A. N., Possible role of serum 25-hydroxyvitamin D in Black-White health disparities in the United States. J. Am. Med. Directors Assoc. 2010, 11, 617-628.
123. Grant, W. B., Peiris, A. N., Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and White Americans. Dermatoendocrinology 2012, 4, 85-94.
124. Freedman, B. I., Wagenknecht, L. E., Hairston, K. G., Bowden, D. W. et al., Vitamin D, adiposity, and calcified atherosclerotic plaque in African-Americans. J. Clin. Endocrinol. Metab. 2010, 95, 1076-1083.
125. Hood, L., Rowen, L. The Human Genome Project: big science transforms biology and medicine. Genom. Med. 2013, 5, 1-8.
126. Kotze, M. J., Lückhoff, H. K., Peeters, A. V., Baatjes, K. et al., Genomic medicine and risk prediction across the disease spectrum. Crit. Rev. Clin. Lab. Sci. 2015, 52, 120-137.
127. Hayden, E. C., Is the $1, 000 Genome for Real? 2014. Available at: http://www.nature.com/news/is-the-1-000-genome-for-real-1.14530
128. Tripp, S., Grueber, M., Economic impact of the Human Genome Project. Battelle Memorial Inst. 2011. Available at: http://battelle.org/docs/default-document-library/economic_impact_of_the_human_genome_project.pdf
129. Batelle Technology Partnership Practice. Impact of Genomics on the US Economy. 2013. Available at: http://www.unitedformedicalresearch.com/advocacy_reports/the-impact-of-genomics-on-the-u-s-economy/
130. Gibson, P. R., Vaizey, C., Black, C. M., Nicholls, R. et al., Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study. J. Crohns Colitis 2014, 8, 598-606.